All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

fampridine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4163	504-24-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fampyra dalfampridine ampyra pyridin-4-amine 4-aminopyridine fampridine	One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes. Molecular weight: 94.12 Formula: C5H6N2 CLOGP: 0.32 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 38.91 ALOGS: 0.46 ROTB: 0

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	90.30 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.04 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	2.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 22, 2010	FDA	ACORDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	1791.47	14.85	787	36003	42177	50526157
Urinary tract infection	1388.49	14.85	1207	35583	222813	50345521
Laboratory test abnormal	1004.39	14.85	437	36353	22771	50545563
Balance disorder	701.52	14.85	504	36286	70086	50498248
Multiple sclerosis	674.55	14.85	319	36471	20174	50548160
Fall	611.71	14.85	963	35827	333969	50234365
Urine analysis abnormal	595.92	14.85	191	36599	4159	50564175
Gait disturbance	554.41	14.85	611	36179	149394	50418940
Therapy cessation	475.64	14.85	273	36517	25738	50542596
Muscular weakness	378.39	14.85	403	36387	94610	50473724
Seizure	265.39	14.85	375	36415	117499	50450835
Insomnia	222.38	14.85	430	36360	174435	50393899
Escherichia urinary tract infection	216.77	14.85	119	36671	10276	50558058
Muscle spasticity	215.88	14.85	142	36648	17042	50551292
Peroneal nerve palsy	195.98	14.85	84	36706	4199	50564135
Gait inability	176.07	14.85	173	36617	36854	50531480
Dizziness	155.53	14.85	578	36212	345791	50222543
Lymphocyte count decreased	152.06	14.85	137	36653	26170	50542164
B-lymphocyte count decreased	149.81	14.85	46	36744	864	50567470
Secondary progressive multiple sclerosis	146.72	14.85	49	36741	1217	50567117
Memory impairment	143.40	14.85	228	36562	79132	50489202
Inappropriate schedule of product administration	139.01	14.85	213	36577	71618	50496716
Central nervous system lesion	137.97	14.85	86	36704	9403	50558931
Hypoaesthesia	136.68	14.85	292	36498	126965	50441369
Therapeutic response unexpected	133.87	14.85	103	36687	15812	50552522
Flushing	131.48	14.85	200	36590	66815	50501519
Rheumatoid arthritis	129.11	14.85	4	36786	202546	50365788
Culture urine positive	126.71	14.85	58	36732	3393	50564941
Paraesthesia	124.63	14.85	272	36518	119971	50448363
Asthenia	121.67	14.85	506	36284	318536	50249798
Toxicity to various agents	117.40	14.85	10	36780	212489	50355845
Drug ineffective	114.43	14.85	997	35793	818336	49749998
Urine leukocyte esterase positive	113.91	14.85	51	36739	2832	50565502
Micturition urgency	107.94	14.85	70	36720	8194	50560140
Dyspnoea	106.53	14.85	146	36644	547462	50020872
Mobility decreased	105.55	14.85	200	36590	79748	50488586
Pollakiuria	105.17	14.85	107	36683	23744	50544590
Off label use	95.76	14.85	123	36667	474303	50094031
Lymphopenia	95.52	14.85	84	36706	15537	50552797
Urinary incontinence	93.71	14.85	109	36681	28099	50540235
JC polyomavirus test positive	90.31	14.85	33	36757	1076	50567258
Anaemia	89.19	14.85	36	36754	252420	50315914
Systemic lupus erythematosus	88.78	14.85	3	36787	140619	50427715
Product substitution issue	84.77	14.85	75	36715	13982	50554352
Depression	84.15	14.85	288	36502	165135	50403199
Head injury	83.46	14.85	95	36695	23925	50544409
Trigeminal neuralgia	82.94	14.85	42	36748	3073	50565261
T-lymphocyte count increased	79.75	14.85	18	36772	91	50568243
Completed suicide	79.29	14.85	4	36786	131885	50436449
Walking aid user	77.96	14.85	52	36738	6381	50561953
Dysstasia	75.04	14.85	78	36712	17741	50550593
CD4 lymphocytes increased	74.27	14.85	18	36772	130	50568204
Joint swelling	73.00	14.85	44	36746	245242	50323092
T-lymphocyte count decreased	72.61	14.85	20	36770	251	50568083
Progressive multiple sclerosis	71.03	14.85	25	36765	730	50567604
Neurogenic bladder	68.79	14.85	36	36754	2821	50565513
Motor dysfunction	67.58	14.85	52	36738	7979	50560355
Exposure during pregnancy	65.96	14.85	6	36784	121009	50447325
Acute kidney injury	64.97	14.85	43	36747	228015	50340319
Glossodynia	62.27	14.85	6	36784	115563	50452771
Infusion related reaction	61.79	14.85	23	36767	169534	50398800
Movement disorder	61.70	14.85	70	36720	17562	50550772
Bladder disorder	61.64	14.85	48	36742	7495	50560839
Red blood cells urine positive	61.26	14.85	33	36757	2742	50565592
Dysgraphia	59.60	14.85	32	36758	2641	50565693
Influenza like illness	58.33	14.85	129	36661	57330	50511004
Arthralgia	57.71	14.85	148	36642	438554	50129780
Neutropenia	57.50	14.85	18	36772	147947	50420387
CD4 lymphocytes decreased	57.13	14.85	25	36765	1314	50567020
White blood cells urine positive	55.46	14.85	37	36753	4541	50563793
Primary progressive multiple sclerosis	55.44	14.85	13	36777	80	50568254
Gait spastic	55.15	14.85	16	36774	245	50568089
Product use issue	54.92	14.85	20	36770	149455	50418879
Contraindicated product administered	54.62	14.85	20	36770	148938	50419396
Maternal exposure during pregnancy	54.43	14.85	24	36766	159754	50408580
CD8 lymphocytes decreased	53.36	14.85	14	36776	144	50568190
Muscle spasms	51.51	14.85	204	36586	125349	50442985
Loss of control of legs	51.35	14.85	23	36767	1278	50567056
Treatment failure	51.28	14.85	18	36772	137619	50430715
Temperature intolerance	51.08	14.85	43	36747	7496	50560838
Product dose omission issue	50.97	14.85	266	36524	183572	50384762
Hypotension	50.59	14.85	58	36732	235411	50332923
Febrile neutropenia	50.24	14.85	6	36784	97661	50470673
Magnetic resonance imaging abnormal	48.22	14.85	28	36762	2690	50565644
Epilepsy	47.48	14.85	68	36722	21499	50546835
Wound	46.57	14.85	10	36780	105784	50462550
Lower respiratory tract infection	46.23	14.85	7	36783	95194	50473140
Progressive multifocal leukoencephalopathy	46.18	14.85	49	36741	11408	50556926
Dysuria	46.16	14.85	78	36712	28426	50539908
Ataxia	45.32	14.85	53	36737	13733	50554601
Rash	45.08	14.85	165	36625	437306	50131028
Burning sensation	44.96	14.85	101	36689	45345	50522989
Lymphocyte count abnormal	44.90	14.85	17	36773	613	50567721
Feeling abnormal	44.50	14.85	195	36595	125297	50443037
Diarrhoea	44.49	14.85	249	36541	588227	49980107
Haemoglobin urine present	44.24	14.85	18	36772	788	50567546
Sinusitis	43.58	14.85	36	36754	170522	50397812
Adverse drug reaction	43.13	14.85	112	36678	55110	50513224
Ankle fracture	41.30	14.85	54	36736	15668	50552666
Urine abnormality	41.07	14.85	35	36755	6203	50562131
Hemiparesis	40.93	14.85	61	36729	19987	50548347
Escherichia test positive	40.85	14.85	23	36767	2084	50566250
Urine odour abnormal	39.22	14.85	32	36758	5341	50562993
Extra dose administered	38.68	14.85	31	36759	5045	50563289
Nitrite urine present	38.55	14.85	17	36773	910	50567424
Invasive ductal breast carcinoma	38.53	14.85	33	36757	5888	50562446
Stomatitis	38.18	14.85	13	36777	101331	50467003
Vitamin B12 increased	38.15	14.85	15	36775	600	50567734
Relapsing-remitting multiple sclerosis	37.84	14.85	14	36776	473	50567861
Arthropathy	37.14	14.85	36	36754	157870	50410464
Weight increased	36.93	14.85	56	36734	201835	50366499
Drug interaction	36.87	14.85	55	36735	199566	50368768
Pneumonia	36.83	14.85	146	36644	378255	50190079
Tremor	36.59	14.85	173	36617	114730	50453604
Gastrointestinal haemorrhage	36.50	14.85	5	36785	73316	50495018
Optic neuritis	36.13	14.85	34	36756	6856	50561478
Pleural effusion	35.24	14.85	8	36782	81446	50486888
Drug hypersensitivity	35.03	14.85	82	36708	250928	50317406
General symptom	34.98	14.85	22	36768	2441	50565893
Pancytopenia	34.89	14.85	9	36781	84021	50484313
Swelling	34.58	14.85	58	36732	200814	50367520
Urinary tract infection pseudomonal	34.46	14.85	15	36775	778	50567556
Musculoskeletal disorder	34.29	14.85	52	36738	17297	50551037
Vomiting	33.66	14.85	197	36593	460561	50107773
Urinary tract infection bacterial	32.97	14.85	26	36764	4133	50564201
Wheelchair user	32.95	14.85	28	36762	4944	50563390
Drug intolerance	32.67	14.85	69	36721	219035	50349299
Abdominal pain	32.30	14.85	78	36712	236150	50332184
Acute disseminated encephalomyelitis	32.16	14.85	10	36780	196	50568138
Hip fracture	31.89	14.85	63	36727	25868	50542466
Platelet count decreased	31.45	14.85	17	36773	100709	50467625
Product use in unapproved indication	31.40	14.85	23	36767	115796	50452538
Cystitis	31.38	14.85	87	36703	44477	50523857
Pain	30.88	14.85	271	36519	578632	49989702
Respiratory failure	30.56	14.85	14	36776	91167	50477167
Prescribed underdose	30.39	14.85	47	36743	15902	50552432
Lymphocyte percentage decreased	30.32	14.85	21	36769	2739	50565595
Cognitive disorder	29.95	14.85	85	36705	44038	50524296
Tongue biting	29.87	14.85	16	36774	1314	50567020
Blood immunoglobulin M decreased	29.23	14.85	13	36777	710	50567624
B-lymphocyte count abnormal	28.95	14.85	7	36783	50	50568284
Blister	28.80	14.85	13	36777	85405	50482929
Glycosylated haemoglobin increased	28.75	14.85	37	36753	10569	50557765
Sensory disturbance	28.57	14.85	39	36751	11790	50556544
Muscle tightness	28.08	14.85	36	36754	10244	50558090
Thrombocytopenia	27.87	14.85	31	36759	127642	50440692
Cardiac arrest	27.79	14.85	13	36777	83638	50484696
Generalised tonic-clonic seizure	27.74	14.85	60	36730	26250	50542084
Hypokinesia	27.60	14.85	39	36751	12178	50556156
Intentional overdose	27.31	14.85	6	36784	62498	50505836
Headache	26.96	14.85	517	36273	506018	50062316
Invasive lobular breast carcinoma	26.85	14.85	12	36778	663	50567671
Overdose	26.78	14.85	20	36770	99707	50468627
Stress	26.71	14.85	93	36697	53700	50514634
Breast cancer	26.59	14.85	80	36710	42810	50525524
Diplopia	26.40	14.85	49	36741	19211	50549123
Coordination abnormal	26.32	14.85	37	36753	11497	50556837
Limb discomfort	26.20	14.85	56	36734	24301	50544033
Bacterial test positive	26.11	14.85	24	36766	4699	50563635
Incontinence	25.77	14.85	34	36756	9951	50558383
Decreased appetite	25.40	14.85	69	36721	200854	50367480
Protein urine present	25.30	14.85	25	36765	5352	50562982
Status epilepticus	24.84	14.85	39	36751	13367	50554967
Fatigue	24.84	14.85	681	36109	706920	49861414
Insurance issue	24.79	14.85	18	36772	2530	50565804
Immune reconstitution inflammatory syndrome	24.77	14.85	25	36765	5491	50562843
Hypoxia	24.27	14.85	4	36786	51119	50517215
Pyrexia	23.93	14.85	170	36620	380033	50188301
Urinary sediment present	23.90	14.85	16	36774	1975	50566359
Urine ketone body present	23.88	14.85	17	36773	2316	50566018
Hyponatraemia	23.67	14.85	21	36769	96118	50472216
Urinary retention	23.47	14.85	56	36734	26134	50542200
Oxygen saturation decreased	23.39	14.85	12	36778	73236	50495098
Paraparesis	23.37	14.85	16	36774	2048	50566286
Lower limb fracture	23.08	14.85	39	36751	14207	50554127
Infection	22.92	14.85	58	36732	172896	50395438
General physical health deterioration	22.81	14.85	43	36747	142391	50425943
Blood thyroid stimulating hormone decreased	22.67	14.85	21	36769	4151	50564183
Decreased interest	22.30	14.85	18	36772	2958	50565376
Hyperkalaemia	22.30	14.85	4	36786	48085	50520249
Skin laceration	22.24	14.85	45	36745	18797	50549537
Lymphocyte percentage abnormal	22.03	14.85	5	36785	26	50568308
Proteus test positive	21.63	14.85	7	36783	157	50568177
Hypersensitivity	21.54	14.85	82	36708	215079	50353255
International normalised ratio increased	21.34	14.85	3	36787	43149	50525185
Back pain	21.26	14.85	249	36541	219781	50348553
Urinary tract infection enterococcal	21.00	14.85	16	36774	2418	50565916
Feeling hot	20.53	14.85	69	36721	39133	50529201
Cystitis klebsiella	20.51	14.85	7	36783	186	50568148
Human papilloma virus test positive	20.46	14.85	9	36781	479	50567855
Red blood cell count abnormal	20.42	14.85	11	36779	914	50567420
Asthma	20.26	14.85	21	36769	89316	50479018
Urge incontinence	20.12	14.85	10	36780	703	50567631
Cardiac failure congestive	20.10	14.85	19	36771	84363	50483971
Impaired healing	20.05	14.85	13	36777	69773	50498561
Psoriasis	19.63	14.85	13	36777	68987	50499347
Initial insomnia	19.08	14.85	21	36769	5094	50563240
Speech disorder	19	14.85	63	36727	35485	50532849
Folliculitis	18.77	14.85	3	36787	39222	50529112
Therapeutic response changed	18.65	14.85	10	36780	823	50567511
Anaphylactic reaction	18.58	14.85	8	36782	54047	50514287
Metabolic acidosis	18.51	14.85	3	36787	38822	50529512
Urinary tract infection staphylococcal	18.45	14.85	7	36783	254	50568080
Peripheral swelling	18.41	14.85	82	36708	205854	50362480
Rectal haemorrhage	18.34	14.85	3	36787	38555	50529779
Hypoglycaemia	18.30	14.85	8	36782	53573	50514761
Cardiac failure	18.25	14.85	17	36773	76023	50492311
Depressed mood	17.92	14.85	60	36730	33963	50534371
Tachycardia	17.91	14.85	28	36762	99735	50468599
Bone pain	17.88	14.85	6	36784	47223	50521111
Living in residential institution	17.62	14.85	8	36782	459	50567875
Neutrophil percentage increased	17.34	14.85	15	36775	2712	50565622
Therapeutic product effect incomplete	17.09	14.85	25	36765	91490	50476844
Urinary tract disorder	17.00	14.85	14	36776	2366	50565968
Bladder dysfunction	16.78	14.85	9	36781	741	50567593
Mean cell haemoglobin decreased	16.67	14.85	16	36774	3307	50565027
CD4 lymphocyte percentage decreased	16.61	14.85	3	36787	3	50568331
Multiple organ dysfunction syndrome	16.44	14.85	8	36782	50329	50518005
Transferrin saturation decreased	16.44	14.85	8	36782	537	50567797
Haematocrit abnormal	16.41	14.85	9	36781	775	50567559
Citrobacter infection	16.38	14.85	7	36783	347	50567987
Vitamin D decreased	16.34	14.85	25	36765	8381	50559953
Postictal paralysis	16.33	14.85	5	36785	93	50568241
Disease progression	16.19	14.85	28	36762	95838	50472496
Intraductal proliferative breast lesion	16.16	14.85	14	36776	2536	50565798
Death	16.12	14.85	155	36635	325224	50243110
Hypertonic bladder	16.11	14.85	15	36775	2985	50565349
Arthritis	15.89	14.85	24	36766	86697	50481637
Electrocardiogram QT prolonged	15.84	14.85	9	36781	51877	50516457
Injection site scar	15.74	14.85	9	36781	840	50567494
Bacterial test	15.60	14.85	10	36780	1147	50567187
Cardio-respiratory arrest	15.54	14.85	10	36780	53882	50514452
Renal failure	15.53	14.85	34	36756	106599	50461735
B-lymphocyte count increased	15.50	14.85	5	36785	111	50568223
Dysarthria	15.49	14.85	61	36729	37342	50530992
Focal dyscognitive seizures	15.33	14.85	14	36776	2718	50565616
Decreased vibratory sense	15.31	14.85	6	36784	238	50568096
Haematochezia	15.21	14.85	5	36785	39877	50528457
Cough	15.09	14.85	108	36682	241156	50327178

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	899.12	20.15	288	12148	11131	29550960
Multiple sclerosis	432.08	20.15	139	12297	5415	29556676
Laboratory test abnormal	304.92	20.15	150	12286	18035	29544056
Balance disorder	298.62	20.15	187	12249	35983	29526108
Urinary tract infection	285.82	20.15	239	12197	72115	29489976
Gait disturbance	258.50	20.15	227	12209	73122	29488969
Fall	255.07	20.15	341	12095	176837	29385254
Muscle spasticity	222.67	20.15	82	12354	4801	29557290
Drug ineffective	197.09	20.15	454	11982	362716	29199375
Muscular weakness	146.15	20.15	154	12282	61898	29500193
Insomnia	130.39	20.15	173	12263	88588	29473503
Central nervous system lesion	129.84	20.15	58	12378	5590	29556501
Mobility decreased	126.71	20.15	97	12339	25683	29536408
Relapsing-remitting multiple sclerosis	121.62	20.15	33	12403	699	29561392
Gait spastic	118.83	20.15	32	12404	658	29561433
Therapy cessation	112.20	20.15	72	12364	14390	29547701
Needle fatigue	99.45	20.15	27	12409	573	29561518
B-lymphocyte count decreased	98.19	20.15	26	12410	500	29561591
Movement disorder	97.26	20.15	58	12378	10179	29551912
Ataxia	95.72	20.15	61	12375	12042	29550049
Memory impairment	95.68	20.15	96	12340	36374	29525717
Seizure	85.76	20.15	146	12290	92977	29469114
Secondary progressive multiple sclerosis	82.52	20.15	21	12415	343	29561748
Micturition urgency	81.63	20.15	41	12395	5132	29556959
Hypertonic bladder	75.88	20.15	27	12409	1429	29560662
Gait inability	72.88	20.15	61	12375	18314	29543777
Monoparesis	68.83	20.15	27	12409	1876	29560215
Pollakiuria	66.76	20.15	56	12380	16860	29545231
Flushing	66.43	20.15	71	12365	28921	29533170
Therapeutic response unexpected	64.50	20.15	42	12394	8596	29553495
Peroneal nerve palsy	63.53	20.15	28	12408	2611	29559480
Product substitution issue	59.83	20.15	41	12395	9131	29552960
Acute kidney injury	57.51	20.15	20	12416	265247	29296844
Trigeminal neuralgia	57.25	20.15	20	12416	1002	29561089
JC polyomavirus test positive	55.52	20.15	17	12419	559	29561532
Anaemia	53.38	20.15	10	12426	200941	29361150
Hypotension	53.08	20.15	9	12427	194345	29367746
Influenza like illness	52.68	20.15	58	12378	24412	29537679
Hypoaesthesia	52.02	20.15	86	12350	53381	29508710
Progressive multifocal leukoencephalopathy	49.94	20.15	36	12400	8683	29553408
Dizziness	48.33	20.15	182	12254	189502	29372589
Lymphocyte count decreased	43.78	20.15	47	12389	19224	29542867
Asthenia	43.32	20.15	192	12244	215058	29347033
Paraesthesia	42.49	20.15	79	12357	53766	29508325
Toxicity to various agents	41.36	20.15	11	12425	173650	29388441
Drug interaction	39.22	20.15	17	12419	197368	29364723
Urinary incontinence	38.86	20.15	41	12395	16440	29545651
Lymphocyte percentage decreased	37.85	20.15	18	12418	1999	29560092
Inappropriate schedule of product administration	37.30	20.15	67	12369	44405	29517686
Urine analysis abnormal	36.49	20.15	17	12419	1803	29560288
Progressive multiple sclerosis	36.32	20.15	10	12426	224	29561867
Dyspnoea	36.15	20.15	51	12385	326681	29235410
Nocturia	35.73	20.15	29	12407	8333	29553758
Off label use	35.25	20.15	45	12391	300755	29261336
Neutropenia	34	20.15	7	12429	131704	29430387
T-lymphocyte count decreased	33.65	20.15	9	12427	180	29561911
White blood cells urine positive	33.33	20.15	14	12422	1160	29560931
Dysarthria	33.16	20.15	52	12384	30859	29531232
Vitamin B12 increased	31.90	20.15	9	12427	221	29561870
Decreased vibratory sense	31.74	20.15	10	12426	362	29561729
Cognitive disorder	31.64	20.15	44	12392	23455	29538636
Renal failure	31.24	20.15	6	12430	118593	29443498
Walking aid user	30.24	20.15	14	12422	1463	29560628
CD8 lymphocytes decreased	30.23	20.15	7	12429	75	29562016
Cystitis	29.74	20.15	26	12410	8266	29553825
Thrombocytopenia	29.43	20.15	10	12426	134813	29427278
Adverse drug reaction	28.00	20.15	42	12394	23978	29538113
Bladder disorder	26.97	20.15	16	12420	2778	29559313
Back pain	25.02	20.15	97	12339	102187	29459904
Paraparesis	24.98	20.15	13	12423	1751	29560340
Burning sensation	24.76	20.15	32	12404	15906	29546185
Musculoskeletal stiffness	24.72	20.15	51	12385	37407	29524684
Pancytopenia	24.65	20.15	3	12433	83165	29478926
Dysstasia	24.59	20.15	26	12410	10448	29551643
Muscle spasms	24.13	20.15	71	12365	65011	29497080
General symptom	23.93	20.15	10	12426	818	29561273
Herpes zoster	23.57	20.15	44	12392	30008	29532083
Neurogenic bladder	23.32	20.15	12	12424	1578	29560513
Erectile dysfunction	23.17	20.15	33	12403	17976	29544115
Spinal cord injury cauda equina	21.32	20.15	6	12430	146	29561945
Temperature intolerance	21.30	20.15	14	12422	2907	29559184
Somatosensory evoked potentials abnormal	21.09	20.15	6	12430	152	29561939
Depression	21.01	20.15	81	12355	85066	29477025
Cardiac failure	20.89	20.15	4	12432	79283	29482808
Platelet count decreased	20.78	20.15	9	12427	104663	29457428
Urosepsis	20.61	20.15	24	12412	10722	29551369
Fatigue	20.44	20.15	213	12223	316608	29245483
T-lymphocyte count increased	20.32	20.15	3	12433	0	29562091
Vitamin B6 deficiency	20.28	20.15	6	12430	175	29561916
Generalised tonic-clonic seizure	20.24	20.15	32	12404	19107	29542984

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	2014.04	15.24	787	35764	40348	64421833
Urinary tract infection	1670.37	15.24	1230	35321	230366	64231815
Laboratory test abnormal	1620.75	15.24	582	35969	23481	64438700
Multiple sclerosis	684.40	15.24	292	36259	18649	64443532
Urine analysis abnormal	639.38	15.24	203	36348	5553	64456628
Fall	632.43	15.24	962	35589	415864	64046317
Balance disorder	608.79	15.24	449	36102	83477	64378704
Gait disturbance	413.58	15.24	498	36053	171657	64290524
Therapy cessation	327.42	15.24	213	36338	32276	64429905
Muscular weakness	314.77	15.24	374	36177	126964	64335217
Muscle spasticity	291.20	15.24	156	36395	16513	64445668
B-lymphocyte count decreased	262.10	15.24	71	36480	1090	64461091
Escherichia urinary tract infection	257.26	15.24	129	36422	11908	64450273
Seizure	223.51	15.24	365	36186	166527	64295654
Insomnia	194.50	15.24	378	36173	197458	64264723
Central nervous system lesion	187.81	15.24	104	36447	11745	64450436
Gait inability	181.19	15.24	167	36384	42201	64419980
Peroneal nerve palsy	165.91	15.24	74	36477	5247	64456934
Lymphocyte count decreased	157.91	15.24	152	36399	40547	64421634
Pollakiuria	154.04	15.24	134	36417	31396	64430785
Gait spastic	153.05	15.24	44	36507	848	64461333
Micturition urgency	150.82	15.24	86	36465	10273	64451908
Culture urine positive	146.53	15.24	63	36488	4088	64458093
Memory impairment	143.51	15.24	208	36343	85474	64376707
Secondary progressive multiple sclerosis	142.80	15.24	45	36506	1198	64460983
Toxicity to various agents	139.83	15.24	20	36531	363493	64098688
Urine leukocyte esterase positive	134.61	15.24	56	36495	3347	64458834
Relapsing-remitting multiple sclerosis	130.99	15.24	41	36510	1067	64461114
Dizziness	128.89	15.24	533	36018	429630	64032551
Hypoaesthesia	124.80	15.24	256	36295	138852	64323329
Mobility decreased	123.30	15.24	194	36357	85646	64376535
Therapeutic response unexpected	123.07	15.24	91	36460	16910	64445271
Movement disorder	122.87	15.24	101	36450	21899	64440282
Anaemia	118.40	15.24	34	36517	378646	64083535
Asthenia	110.31	15.24	507	36044	427537	64034644
Acute kidney injury	109.84	15.24	59	36492	449181	64013000
Urinary incontinence	107.48	15.24	117	36434	36034	64426147
T-lymphocyte count decreased	106.27	15.24	29	36522	458	64461723
JC polyomavirus test positive	105.81	15.24	36	36515	1226	64460955
Paraesthesia	102.77	15.24	232	36319	134290	64327891
T-lymphocyte count increased	102.66	15.24	21	36530	82	64462099
Dyspnoea	98.62	15.24	160	36391	718514	63743667
Inappropriate schedule of product administration	96.24	15.24	181	36370	92105	64370076
Trigeminal neuralgia	96.16	15.24	43	36508	3066	64459115
Off label use	93.40	15.24	134	36417	632672	63829509
White blood cells urine positive	90.00	15.24	49	36502	5349	64456832
Progressive multifocal leukoencephalopathy	88.05	15.24	77	36474	18155	64444026
Flushing	86.70	15.24	158	36393	78490	64383691
Ataxia	86.61	15.24	83	36468	22001	64440180
Febrile neutropenia	86.20	15.24	5	36546	187652	64274529
Hypotension	86.04	15.24	55	36496	380919	64081262
Needle fatigue	83.29	15.24	25	36526	563	64461618
CD8 lymphocytes decreased	83.14	15.24	21	36530	241	64461940
Completed suicide	82.46	15.24	14	36537	224400	64237781
CD4 lymphocytes increased	81.68	15.24	21	36530	260	64461921
Head injury	80.19	15.24	96	36455	32746	64429435
Rheumatoid arthritis	79.91	15.24	3	36548	164291	64297890
Neutropenia	77.67	15.24	20	36531	239604	64222577
Red blood cells urine positive	75.63	15.24	41	36510	4437	64457744
Lymphopenia	71.01	15.24	80	36471	25577	64436604
Product substitution issue	67.91	15.24	66	36485	17795	64444386
Drug interaction	66.90	15.24	64	36487	362019	64100162
Lymphocyte percentage decreased	66.07	15.24	38	36513	4611	64457570
Hypertonic bladder	65.37	15.24	34	36517	3384	64458797
Dysstasia	65.30	15.24	73	36478	23142	64439039
Vitamin B12 increased	64.25	15.24	21	36530	630	64461551
CD4 lymphocytes decreased	63.77	15.24	30	36521	2405	64459776
Neurogenic bladder	63.54	15.24	34	36517	3585	64458596
Dysuria	60.27	15.24	95	36456	41962	64420219
Monoparesis	58.46	15.24	30	36521	2904	64459277
Motor dysfunction	56.87	15.24	49	36502	11324	64450857
Progressive multiple sclerosis	56.29	15.24	20	36531	776	64461405
Walking aid user	55.56	15.24	38	36513	6243	64455938
Influenza like illness	53.43	15.24	112	36439	61590	64400591
Bladder disorder	52.70	15.24	40	36511	7727	64454454
Haemoglobin urine present	51.03	15.24	19	36532	844	64461337
Depression	49.92	15.24	221	36330	183070	64279111
Cystitis	49.91	15.24	88	36463	42587	64419594
Pancytopenia	48.29	15.24	11	36540	143298	64318883
Diarrhoea	47.88	15.24	229	36322	722475	63739706
Primary progressive multiple sclerosis	47.57	15.24	11	36540	84	64462097
Lymphocyte count abnormal	47.03	15.24	18	36533	863	64461318
Nitrite urine present	47.03	15.24	19	36532	1053	64461128
Gastrointestinal haemorrhage	46.96	15.24	9	36542	132303	64329878
Drug ineffective	45.80	15.24	698	35853	839549	63622632
Urine abnormality	45.77	15.24	36	36515	7326	64454855
Glycosylated haemoglobin increased	44.41	15.24	50	36501	15969	64446212
Product dose omission issue	44.40	15.24	223	36328	194524	64267657
Ankle fracture	44.39	15.24	48	36503	14662	64447519
Product use issue	43.14	15.24	16	36535	151699	64310482
Thrombocytopenia	43.14	15.24	38	36513	223763	64238418
Urinary tract infection bacterial	42.99	15.24	30	36521	5091	64457090
Magnetic resonance imaging abnormal	42.98	15.24	25	36526	3098	64459083
Escherichia test positive	42.59	15.24	24	36527	2801	64459380
Bacterial test positive	42.21	15.24	33	36518	6657	64455524
Joint swelling	42.20	15.24	36	36515	215346	64246835
Urinary tract infection pseudomonal	41.70	15.24	19	36532	1415	64460766
Loss of control of legs	41.64	15.24	20	36531	1679	64460502
Hip fracture	41.32	15.24	63	36488	27036	64435145
Invasive ductal breast carcinoma	41.07	15.24	29	36522	5013	64457168
Muscle spasms	40.65	15.24	173	36378	140850	64321331
Temperature intolerance	40.13	15.24	35	36516	8220	64453961
Blood thyroid stimulating hormone decreased	40.12	15.24	29	36522	5201	64456980
B-lymphocyte count abnormal	39.12	15.24	9	36542	67	64462114
Decreased appetite	38.99	15.24	62	36489	281227	64180954
Feeling abnormal	38.58	15.24	164	36387	133438	64328743
Dysarthria	38.32	15.24	96	36455	59310	64402871
Urine odour abnormal	38.31	15.24	28	36523	5108	64457073
Status epilepticus	38.29	15.24	54	36497	21609	64440572
Blood immunoglobulin M decreased	38.27	15.24	16	36535	968	64461213
Platelet count decreased	38.08	15.24	24	36527	167687	64294494
Multiple organ dysfunction syndrome	37.95	15.24	6	36545	101407	64360774
Paraparesis	37.82	15.24	24	36527	3478	64458703
Epilepsy	37.73	15.24	68	36483	33463	64428718
Generalised tonic-clonic seizure	37.63	15.24	75	36476	39782	64422399
Renal failure	37.29	15.24	29	36522	181659	64280522
Pneumonia	37.17	15.24	177	36374	559399	63902782
Lower respiratory tract infection	36.79	15.24	5	36546	94609	64367572
General symptom	36.52	15.24	20	36531	2208	64459973
Tremor	36.10	15.24	173	36378	148057	64314124
Infusion related reaction	35.37	15.24	25	36526	164442	64297739
Drug hypersensitivity	35.29	15.24	50	36501	237765	64224416
Musculoskeletal disorder	35.21	15.24	47	36504	17859	64444322
Acute disseminated encephalomyelitis	35.04	15.24	11	36540	289	64461892
Nocturia	34.69	15.24	37	36514	11128	64451053
Hemiparesis	34.22	15.24	61	36490	29766	64432415
Urine ketone body present	34.06	15.24	22	36529	3285	64458896
Hyponatraemia	33.99	15.24	21	36530	148318	64313863
Protein urine present	33.87	15.24	33	36518	8923	64453258
Hyperkalaemia	33.59	15.24	8	36543	101121	64361060
Extra dose administered	33.58	15.24	29	36522	6721	64455460
Hypoxia	33.47	15.24	5	36546	88144	64374037
Immune reconstitution inflammatory syndrome	33.00	15.24	38	36513	12432	64449749
Cardiac failure	32.83	15.24	17	36534	132356	64329825
Abdominal pain	32.82	15.24	81	36470	312294	64149887
Respiratory failure	32.73	15.24	26	36525	161157	64301024
Neutrophil percentage increased	32.63	15.24	24	36527	4421	64457760
Cardiac arrest	32.37	15.24	24	36527	154040	64308141
Treatment failure	32.08	15.24	13	36538	116803	64345378
Cardiac failure congestive	32.04	15.24	17	36534	130563	64331618
Pleural effusion	31.76	15.24	16	36535	126543	64335638
Drug intolerance	31.54	15.24	36	36515	187956	64274225
Breast cancer	31.39	15.24	58	36493	29090	64433091
International normalised ratio increased	31.22	15.24	4	36547	79163	64383018
Cystitis klebsiella	30.98	15.24	10	36541	288	64461893
Prescribed underdose	30.51	15.24	44	36507	17971	64444210
Urosepsis	30.40	15.24	49	36502	22045	64440136
Metabolic acidosis	29.44	15.24	3	36548	70955	64391226
Cognitive disorder	29.42	15.24	83	36468	55004	64407177
Rhabdomyolysis	29.04	15.24	8	36543	91718	64370463
Weight increased	28.63	15.24	48	36503	213300	64248881
Overdose	28.50	15.24	29	36522	159537	64302644
Muscle tightness	27.96	15.24	33	36518	11082	64451099
Oxygen saturation decreased	27.73	15.24	13	36538	107163	64355018
Decreased vibratory sense	27.69	15.24	11	36540	583	64461598
Wheelchair user	27.24	15.24	22	36529	4650	64457531
Rash	27.05	15.24	151	36400	458398	64003783
Burning sensation	26.69	15.24	75	36476	49589	64412592
Back pain	26.68	15.24	237	36314	249934	64212247
Urinary tract infection enterococcal	26.63	15.24	18	36533	2900	64459281
Vitamin D decreased	26.62	15.24	27	36524	7660	64454521
Sensory disturbance	26.48	15.24	35	36516	13173	64449008
Hypoglycaemia	26.36	15.24	9	36542	89883	64372298
Exposure during pregnancy	26.08	15.24	6	36545	77669	64384512
CD8 lymphocyte percentage decreased	25.91	15.24	4	36547	0	64462181
Urinary sediment present	25.86	15.24	16	36535	2218	64459963
Stomatitis	25.83	15.24	15	36536	109590	64352591
Vomiting	25.66	15.24	195	36356	550922	63911259
CD8 lymphocytes increased	25.59	15.24	6	36545	49	64462132
Cardio-respiratory arrest	25.35	15.24	12	36539	98381	64363800
Invasive lobular breast carcinoma	25.09	15.24	10	36541	535	64461646
Pericarditis	25.04	15.24	3	36548	62513	64399668
Disease progression	25.01	15.24	26	36525	141654	64320527
Monocyte percentage increased	24.88	15.24	15	36536	1985	64460196
Insurance issue	24.76	15.24	17	36534	2809	64459372
Intentional overdose	24.71	15.24	10	36541	89934	64372247
Haematochezia	24.66	15.24	4	36547	66369	64395812
Coordination abnormal	24.54	15.24	36	36515	14928	64447253
Neutrophil count increased	24.52	15.24	48	36503	25126	64437055
Decreased interest	24.34	15.24	18	36533	3342	64458839
Lower limb fracture	24.29	15.24	34	36517	13511	64448670
Headache	23.94	15.24	427	36124	529040	63933141
Optic neuritis	23.64	15.24	26	36525	8090	64454091
Hepatic function abnormal	23.62	15.24	4	36547	64309	64397872
Arthralgia	23.25	15.24	151	36400	442109	64020072
General physical health deterioration	23.06	15.24	51	36500	204374	64257807
Human papilloma virus test positive	23.04	15.24	9	36542	456	64461725
Urinary tract disorder	23.03	15.24	17	36534	3149	64459032
Red blood cell count abnormal	22.90	15.24	12	36539	1212	64460969
Pyrexia	22.67	15.24	205	36346	558439	63903742
Vitamin B12 abnormal	22.40	15.24	6	36545	88	64462093
Lymphocyte percentage abnormal	22.00	15.24	5	36546	35	64462146
Glossodynia	21.72	15.24	5	36546	64691	64397490
Feeling hot	21.70	15.24	66	36485	45597	64416584
Urinary tract infection staphylococcal	21.58	15.24	10	36541	774	64461407
Visual impairment	21.42	15.24	91	36460	73986	64388195
Blood thyroid stimulating hormone increased	21.40	15.24	24	36527	7630	64454551
Tongue biting	21.38	15.24	13	36538	1747	64460434
Pulmonary oedema	21.20	15.24	9	36542	78665	64383516
CD4 lymphocyte percentage decreased	21.20	15.24	4	36547	9	64462172
Limb discomfort	20.86	15.24	47	36504	27128	64435053
Mean cell haemoglobin increased	20.65	15.24	16	36535	3186	64458995
Vitamin D abnormal	20.57	15.24	6	36545	122	64462059
Ascites	20.40	15.24	5	36546	61996	64400185
Blood urine present	20.38	15.24	37	36514	18303	64443878
Septic shock	20.18	15.24	18	36533	105419	64356762
Erectile dysfunction	20.16	15.24	30	36521	12597	64449584
Product use in unapproved indication	19.97	15.24	44	36507	176574	64285607
Urinary sediment abnormal	19.83	15.24	6	36545	139	64462042
B-lymphocyte count increased	19.75	15.24	6	36545	141	64462040
Glucose urine present	19.68	15.24	12	36539	1620	64460561
Blood pressure fluctuation	19.56	15.24	3	36548	51868	64410313
Spinal cord injury cauda equina	19.55	15.24	6	36545	146	64462035
Dysgraphia	19.51	15.24	16	36535	3455	64458726
Expanded disability status scale score increased	19.42	15.24	8	36543	466	64461715
Sinusitis	19.41	15.24	33	36518	145895	64316286
Vitamin B6 deficiency	19.40	15.24	7	36544	284	64461897
Mean cell haemoglobin decreased	19.08	15.24	17	36534	4105	64458076
Proteus test positive	18.84	15.24	7	36544	309	64461872
Contraindicated product administered	18.79	15.24	20	36531	107809	64354372
Urinary retention	18.77	15.24	66	36485	49135	64413046
Fear of falling	18.77	15.24	8	36543	508	64461673
Asthma	18.53	15.24	16	36535	95209	64366972
Skin laceration	18.48	15.24	42	36509	24375	64437806
Citrobacter infection	18.47	15.24	9	36542	780	64461401
Rectal haemorrhage	18.46	15.24	6	36545	61811	64400370
Somatosensory evoked potentials abnormal	18.33	15.24	6	36545	181	64462000
Anaphylactic reaction	18.27	15.24	8	36543	68656	64393525
Neuropathy peripheral	18.13	15.24	24	36527	117501	64344680
Road traffic accident	18.08	15.24	48	36503	30697	64431484
Coma	17.95	15.24	14	36537	87601	64374580
Crystal urine present	17.85	15.24	12	36539	1917	64460264
Bacterial test	17.51	15.24	10	36541	1197	64460984
Swelling	17.23	15.24	41	36510	160177	64302004
Stress	17.22	15.24	74	36477	60460	64401721
Urobilinogen urine increased	17.21	15.24	8	36543	624	64461557
Electrocardiogram QT prolonged	17.17	15.24	12	36539	79436	64382745
Therapeutic product effect incomplete	17.15	15.24	20	36531	103462	64358719
Haemorrhage	17.13	15.24	12	36539	79339	64382842
Rash maculo-papular	17.11	15.24	3	36548	47023	64415158
Musculoskeletal stiffness	17.08	15.24	124	36427	123082	64339099
Tibia fracture	17.04	15.24	17	36534	4728	64457453
Full blood count abnormal	17.04	15.24	46	36505	29711	64432470
Nephrolithiasis	17.01	15.24	59	36492	43624	64418557
Diplopia	16.99	15.24	43	36508	26722	64435459
Therapy interrupted	16.90	15.24	36	36515	20000	64442181
Speech disorder	16.80	15.24	63	36488	48378	64413803
Angioedema	16.77	15.24	7	36544	61814	64400367
Chronic kidney disease	16.64	15.24	6	36545	57913	64404268
White matter lesion	16.62	15.24	11	36540	1711	64460470
Therapeutic response changed	16.59	15.24	9	36542	975	64461206
Lactic acidosis	16.59	15.24	7	36544	61403	64400778
Lymphocyte count increased	16.37	15.24	17	36534	4958	64457223
Urine uric acid decreased	16.36	15.24	5	36546	120	64462061
Wrist fracture	16.31	15.24	24	36527	9977	64452204
Dyspnoea exertional	16.12	15.24	11	36540	73719	64388462
Focal dyscognitive seizures	16.09	15.24	14	36537	3276	64458905
Hypokalaemia	15.82	15.24	28	36523	121875	64340306
COVID-19	15.82	15.24	76	36475	65064	64397117
Renal impairment	15.79	15.24	33	36518	134984	64327197
Respiratory distress	15.76	15.24	5	36546	52326	64409855
Transferrin saturation decreased	15.74	15.24	8	36543	759	64461422
Streptococcal urinary tract infection	15.63	15.24	6	36545	290	64461891
CD4 lymphocytes abnormal	15.60	15.24	4	36547	49	64462132
Urinary tract obstruction	15.56	15.24	15	36536	4002	64458179
Incontinence	15.55	15.24	26	36525	12055	64450126
Maternal exposure during pregnancy	15.39	15.24	19	36532	95865	64366316
Urine cannabinoids increased	15.28	15.24	3	36548	9	64462172

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N07XX07	NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs
FDA MoA	N0000175448	Potassium Channel Antagonists
FDA EPC	N0000192795	Potassium Channel Blocker
CHEBI has role	CHEBI:33289	avicides
CHEBI has role	CHEBI:71031	orphan drugs
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D026902	Potassium Channel Blockers

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Multiple sclerosis	indication	24700007	DOID:2377
Seizure disorder	contraindication	128613002
Impaired renal function disorder	contraindication	197663003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.58	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Voltage-gated potassium channel	Ion channel	O43525 O43526 O95259 P16389 P17658 P22001 P22459 P22460 P48547 P51787 P56696 Q03721 Q09470 Q12809 Q14003 Q14721 Q16322 Q6PIU1 Q8NCM2 Q8TAE7 Q8TDN1 Q8TDN2 Q92953 Q96KK3 Q96L42 Q96PR1 Q96RP8 Q9BQ31 Q9H252 Q9H3M0 Q9NR82 Q9NS40 Q9NSA2 Q9NZV8 Q9UIX4 Q9UJ96 Q9UK17 Q9ULD8 Q9ULS6 Q9UQ05	KCNQ3_HUMAN KCNQ2_HUMAN KCNH1_HUMAN KCNA2_HUMAN KCNA6_HUMAN KCNA3_HUMAN KCNA4_HUMAN KCNA5_HUMAN KCNC1_HUMAN KCNQ1_HUMAN KCNQ4_HUMAN KCNC4_HUMAN KCNA1_HUMAN KCNH2_HUMAN KCNC3_HUMAN KCNB1_HUMAN KCA10_HUMAN KCNV1_HUMAN KCNH5_HUMAN KCNG3_HUMAN KCNG4_HUMAN KCNV2_HUMAN KCNB2_HUMAN KCNS1_HUMAN KCNH8_HUMAN KCNC2_HUMAN KCNA7_HUMAN KCNS3_HUMAN KCNH6_HUMAN KCNF1_HUMAN KCNQ5_HUMAN KCNH7_HUMAN KCND1_HUMAN KCND2_HUMAN KCNG1_HUMAN KCNG2_HUMAN KCND3_HUMAN KCNH3_HUMAN KCNS2_HUMAN KCNH4_HUMAN	BLOCKER	IC50	4.05		CHEMBL	CHEMBL
Potassium voltage-gated channel subfamily C member 1	Ion channel		KCNC1_MOUSE	BLOCKER	IC50	4.50		IUPHAR
Potassium voltage-gated channel subfamily C member 2	Ion channel		KCNC2_RAT	BLOCKER	IC50	4.60		IUPHAR

External reference:

ID	Source
4029704	VUID
N0000180628	NUI
D04127	KEGG_DRUG
4025700	VANDF
4025705	VANDF
4029704	VANDF
C0000477	UMLSCUI
CHEBI:34385	CHEBI
4AP	PDB_CHEM_ID
CHEMBL284348	ChEMBL_ID
DB06637	DRUGBANK_ID
2416	IUPHAR_LIGAND_ID
BH3B64OKL9	UNII
1727	PUBCHEM_CID
897018	RXNORM
170373	MMSL
26967	MMSL
NOCODE	MMSL
d07546	MMSL
006829	NDDF
413355004	SNOMEDCT_US
80994002	SNOMEDCT_US
D015761	MESH_DESCRIPTOR_UI
7283	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0479	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	27 sections
dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0509	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	NDA authorized generic	27 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2533	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	27 sections
AMPYRA	HUMAN PRESCRIPTION DRUG LABEL	1	10144-427	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	NDA	27 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	16729-292	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
DALFAMPRIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-275	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-246	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-246	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
Dalfampridine	Human Prescription Drug Label	1	62756-429	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	27 sections
DALFAMPRIDINE	Human Prescription Drug Label	1	65862-863	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Dalfampridine	Human Prescription Drug Label	1	67877-444	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Dalfampridine	Human Prescription Drug Label	1	67877-444	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections